pharmaphorum April 15, 2021
When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. The pharma organisation prides itself on having an open, collaborative, “science first” approach to help ensure breakthrough discoveries have the very best chance of long-term success in bringing new treatment options to patients worldwide.
“Our mission is to turn innovative science into value for patients and we are working in a lot of different areas with high unmet need,” says Stef Schutte, Astellas’ head of regulatory affairs. “We have a pipeline of novel therapeutics and technological approaches, advancing a diverse array of candidates, including small molecules, biologics and cell and gene therapies, so a lot of the time we are working where there’s little, or no...